Medicus Pharma Ltd. completed the acquisition of 98.6% of the issued and outstanding shares of Antev Limited.
The acquisition involved cash and common shares of Medicus, totaling approximately US$2.97 million and 1,603,164 shares respectively.
Antev is developing Teverelix, a next-generation GnRH antagonist, with potential market opportunities of ~US$6 billion.
Strategic Acquisition
Acquisition strengthens Medicus's drug development pipeline and team, adding expertise from former Antev executives.
Market Potential
Teverelix has a potential market opportunity of approximately US$6 billion, targeting conditions like Acute Urinary Retention and high cardiovascular risk Prostate Cancer.
Leadership Expansion
Key appointments include Patrick J. Mahaffy to the Medicus Board of Directors, enhancing the leadership team with industry experience.
Clinical Development
Antev's plans include phase 2 studies for preventing Acute Urinary Retention recurrence and treating advanced Prostate Cancer patients with high cardiovascular risk.
- The acquisition enhances Medicus's position in the biotech/life sciences industry, offering growth potential in novel therapeutic assets.
- The addition of Antev's expertise and product pipeline augments Medicus's capabilities in addressing critical healthcare needs.
The acquisition of Antev Limited marks a significant milestone for Medicus Pharma Ltd., opening doors to innovative treatments in urology and oncology. With a focus on Teverelix's development, Medicus is poised for further growth and market expansion.